Physician profile
Lauren Herr
NPI 1407570864
$1,741.95
in general payments reported to CMS, 2019-2025
21 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.96 · 2024: $355 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.02 | 2023-2025 | Caplyta |
| Abbvie INC. | $245.04 | 2025 | |
| Lundbeck LLC | $230.13 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $222.93 | 2024-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $184.61 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $97.90 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $85.12 | 2025 | Sublocade |
| Pfizer INC. | $84.59 | 2025 | |
| Vanda Pharmaceuticals INC. | $42.53 | 2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $38.49 | 2024-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $32.85 | 2024 | Uzedy |
| Corium, LLC | $32.70 | 2025 | Azstarys |
| Almirall LLC | $23.28 | 2025 | Seysara |
| Organon LLC | $19.36 | 2024 | |
| Novo Nordisk INC | $17.37 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $16.09 | 2024 | Ingrezza |
| Almatica Pharma LLC | $16.04 | 2024 | Loreev Xr |
| Inspire Medical Systems, INC. | $15.33 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $14.63 | 2025 | Nuzyra |
| Amgen INC. | $14.32 | 2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $13.62 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Herr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.